Evidence map›Paper›PMID 24166742›Full record

Trial reportEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2014

Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Anjali Lepcha, Sophia Amalanathan, Ann Mary Augustine, Amit Kumar Tyagi, Achamma Balraj

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04417361 (A Pilot Trial of Galcanezumab for Vestibular Migraine), which is not on this map. Cited by 44 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 8 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04417361 phase2completednot on this mapstarted 2020, after this paper: background citation

A Pilot Trial of Galcanezumab for Vestibular Migraine

TypeinterventionalSponsorUniversity of California, San FranciscoRan2020 to 2023Enrolled40ConditionsVestibular MigraineArmsGalcanezumab Prefilled Syringe, Placebo
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 8 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacological interventions for prophylaxis of vestibular migraine.The Cochrane database of systematic reviews · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pharmacological agents for the prevention of vestibular migraine.The Cochrane database of systematic reviews · 2015
    Pooled it
  9. Trial
  10. Trial
  11. Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Recent Trends in Treatment of Vestibular Migraine: A Systematic Review.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anjali LepchaDepartment of ENT, Unit IV, Christian Medical College and Hospital, Vellore, 632004, Tamilnadu, India, anjalilepcha@yahoo.com.
Sophia Amalanathan
Ann Mary Augustine
Amit Kumar Tyagi
Achamma Balraj
Christian Medical College & Hospital · INIndira Gandhi Medical College and Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migrainous vertigo is a common cause of dizziness presenting to an otorhinolaryngology/otoneurology clinic. Although it causes a substantial burden to the individual and society there are no randomized controlled trails on prophylactic medication for this condition. Flunarizine, a calcium channel blocker has been used effectively in both migraine and vestibular conditions. This randomized control trial was undertaken in a tertiary academic referral center to evaluate the efficacy of flunarizine in patients with migrainous vertigo when compared to non-specific vestibular treatment of betahistine and vestibular exercises. The effect of flunarizine on two particularly disabling symptoms of vertigo and headache was studied. A total of 48 patients who were diagnosed with definitive migrainous vertigo completed the study of 12 weeks duration. Patients in arm A received 10-mg flunarizine daily along with betahistine 16 mg and paracetamol 1 gm during episodes, and arm B received only betahistine and paracetamol during episodes. Symptom scores were noted at the start of the study and at the end of 12 weeks. Analysis of the frequency of vertiginous episodes showed a significant difference between arm A and arm B (p = 0.010) and improvement in severity of vertigo between the two groups (p = 0.046). Headache frequency and severity did not improve to a significant degree in arm A as compared to arm B. The main side effects were weight gain and somnolence and this was not significantly different between the two groups. Flunarizine (10 mg) is effective in patients with migrainous vertigo who suffer from considerable vestibular symptoms.

Indexed as

AcetaminophenAdolescentAdultAgedBetahistineCalcium Channel BlockersDisorders of Excessive SomnolenceDrug Therapy, CombinationFemaleFlunarizineHistamine AgonistsHistamine AntagonistsHumansMaleMiddle AgedMigraine DisordersAcetaminophenBetahistineCalcium Channel BlockersFlunarizineHistamine AgonistsHistamine Antagonists

Identifiers

PMID24166742
OpenAlexW2165322041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.